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Introduction
Left atrial (LA) size increases in response to long-standing 
hemodynamic or electrical loads.1)2) The incidence of new onset 
atrial fibrillation, heart failure, ischemic stroke, acute coronary 
syndrome, and cardiovascular death increase with an increase 
in LA size.3-5) However, giant left atrium (GLA), which is due to 
excessive LA remodeling, is a rare condition with a prevalence 
of only 0.3–0.6%.6-8) Despite the fact that the terminology 
“GLA” is often used, the cut-off size to diagnose GLA has not 
always been clearly defined, though an LA antero-posterior direc-
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tion (AP) dimension higher than or 65 mm was used in some 
previous reports.6)7) In addition to long-duration loading of the 
left atrium, other factors may also contribute to this rare condi-
tion. Despite uncertainty regarding the underlying patho-
physiologic mechanism, rheumatic mitral valvular disease 
(MVD) is known to be the main cause of GLA, and few stud-
ies reported that mitral regurgitation (MR) from mitral valve 
(MV) prolapse or hypertrophic cardiomyopathy could be relat-
ed to this rare condition.7) However, the actual prevalence, 
contributors, and clinical outcomes of GLA have not previ-
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ously been investigated. In this study, we therefore investigat-
ed GLA clinical characteristics and clinical outcomes. We then 
evaluated predictors for clinical outcome and whether the con-
cept of “the bigger the worse” is applicable to this rare condition.
Methods
Study population and clinical characteristics
This was a single-center, retrospective, observational study. 
The study proposal was approved by the Institutional Review 
Board of our hospital and informed consent was waived due to 
the retrospective nature of the study. From a total of 110009 
consecutive echocardiography cases performed from Jan 2005 
to Dec 2015, cases with an LA-AP diameter 65 mm or greater 
than 65 mm were selected. In cases with repeated examina-
tion, the initial examination was selected. Finally, 163 patients 
(0.24%) among 68519 primary patients were selected for final 
analysis (Fig. 1). The medical records of these 163 patients were 
reviewed and associated data were collected by a study coordi-
nator. History of underlying cardio-cerebro vascular disease and 
previous cardiac surgery were reviewed. In addition, information 
about hypertension, diabetes, dyslipidemia, and current med-
ications were collected. Blood hemoglobin, estimated glo-
merular filtration rate (eGFR), brain natriuretic peptide (BNP) 
(n = 84), and C-reactive protein (CRP) (n = 121) measured 
within 1 year were collected. Significant MVD was defined as 
a moderate or severe degree of stenosis or regurgitation. Pa-
tients with previous MV surgery were included in the signifi-
cant MVD group. 
Clinical outcome assesment
Primary composite end-point for follow-up comprised all-
cause death, new onset cerebrovascular accident (CVA), heart 
failure admission, and acute myocardial infarction. To evaluate 
clinical outcomes, a coordinator reviewed medical records and 
contacted patients or relatives by telephone.
Transthoracic echocardiography
Left ventricular (LV) dimensions and septal and posterior wall 
thicknesses were measured at end-diastole and end-systole in 
the two-dimensional parasternal long axis or short axis views. 
LV ejection fraction was calculated using the Teichholz meth-
od. LV mass was measured by Devereux’s methods as recom-
mended by the American Society of Echocardiography.9) LA 
volume was measured using the prolate ellipsoidal method at 
the point of LV end-systole when LA size was maximal.10)11) 
LA volume index (LAVI) was calculated as divided by body 
surface area. Peak velocity of tricuspid regurgitation (TRV) was 
measured and pulmonary arterial systolic pressure (PASP) was 
calculated as 4 × TRV2 + right atrial (RA) pressure, where RA 
pressure was estimated according to inferior vena cava diameter 
and its respiratory variations.9) Mean pressure gradient through 
the MV were measured by continuous wave Doppler and quan-
tification of MR was done by proximal isovelocity surface area 
methods.12) Severity of valvular regurgitation and stenosis were 
defined according to current guidelines but severity of functional 
MR followed uniformly to primary MR.13)
Statistical analysis
Clinical characteristics and echocardiographic parameters 
Fig. 1. Schematic flow diagram of the study population. TTE: transthoracic echocardiography, MR: mitral regurgitation, MS: mitral stenosis, MV: 
mitral valve, MVD: mitral valvular disease, RHD: rheumatic heart disease.
Antero-posterior diameter ≥ 65 mm
289 subjects
163 subjects
Exclusion: duplication studies
Selection: initial examination of each 
patients
Non-significant MVD
(mild MR or MS or non-MVD)
(n = 50, 30.7%)
Significant MVD
(moderate or severe MR or MS)
(n = 113, 69.3%)
RHD
(n = 68, 60.5%)
RHD
(n = 4, 8%)
Non-RHD
(MV prolaps or congenital 
MVD, Secondary MR)
(n = 45, 39.5%)
Non-RHD
(LV systolic of diastolic
dysfunction)
(n = 46, 92%)
Total 110009 TTE cases
In Jan. 2005–Dec. 2015
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are presented as means ± standard deviations for continuous 
variables and numbers (percentages) for categorical variables. 
The significance of correlations between groups in continuous 
variables was assessed using the Pearson correlation coefficient. 
The significance of differences in clinical and echocardiograph-
ic findings between study groups was evaluated by indepen-
dent t-test for continuous variable or the chi-square test for di-
chotomous variables. Cox proportional hazard regression analysis 
was performed to determine the probability distribution of time 
to each event and composite end-points. The variables not fol-
lowing normal distribution were expressed as median and in-
terquartile range. Mann-Whitney U-test for independent two 
group comparison and log transformed values were used for 
the Cox regression analysis. All analyses were performed using 
SPSS (version 20.0, IBM Corp., Armonk, NY, USA), and p val-
ues less than 0.05 were considered significant.
Results
Baseline clinical characteristics
Mean age of the 163 subjects was 67.5 ± 12.6 years, and 73 
(45%) were female. Main contributors to GLA were rheumatic 
mitral stenosis (n = 58, 36%), rheumatic MR (n = 10, 6%), MR 
due to MV prolapse or congenital MVD (n = 20, 12%), sec-
ondary MR of more than mild degree (n = 25, 15%), mild 
rheumatic mitral stenosis or regurgitation (n = 4, 3%), and sig-
nificant LV dysfunction without significant MR (n = 46, 28%) 
(Fig. 2). Among those patients with significant LV systolic or 
diastolic dysfunction, three patients had hypertrophic cardio-
myopathy and two patients had constrictive pericarditis. Twen-
ty five patients were suspected as restrictive cardiomyopathy. 
Almost all patients had atrial fibrillation (n = 161, 99%), one 
patient had sinus rhythm and remaining patient had ventricu-
Fig. 2. Representative cases of a giant LA. Parasternal long axis view (A) and apical 4-chamber view (B) of rheumatic mitral stenosis. Parasternal 
long axis view (C) and apical 4-chamber view (D) of hypertrophic cardiomyopathy with moderate MR. Parasternal long axis view (E) and apical 
4-chamber view (F) of severe rheumatic MR. Dotted line in C shows antero-posterior diameter of left atrium. LA: left atrium, MR: mitral regurgitation.
A B
C D
E F
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lar pacing rhythm. Of 163 patients, 139 patients (85.3%) were 
taking warfarin and 4 patients (2.4%) were taking novel oral 
anticoagulants. Remainder 20 patients were taking aspirin or 
other antiplatelet agents. Thirty three patients (20%) had pre-
vious history of MV surgery, of them 25 patients underwent 
MV replacement surgery due to rheumatic heart disease (RHD), 
one patient underwent MV repair and 7 patients underwent 
MV replacement (n = 7) due to degenerative MR. The median 
LA-AP diameter and LAVI were 67 (66–71) mm and 118.9 
(100.2–149.1) mL/m2, respectively. The mean LV ejection frac-
tion and PASP were 59.6 ± 12.4% and 46.8 ± 16.2 mm Hg, 
respectively. Mean blood hemoglobin concentration was 12.4 
± 2.6 g/dL and mean eGFR was 67.3 ± 21.7 mL/min/1.73 m2 
(Table 1).
Comparison among groups with different causes 
of GLA
Patients with significant MVD were younger and had a high-
er PASP and LAVI than the other patients. They had a lower 
prevalence of hypertension, beta-blocker use, and lower serum 
BNP level than the other patients (Table 1). When patients were 
assigned to groups based on the presence or absence of RHD, 
we found that RHD patients had a lower LV mass index, BNP 
level, and beta-blocker use and higher LAVI than non-RHD 
patients (Table 2). LA-AP diameter (r = 0.773, p < 0.001), 
LA–medio-lateral direction (ML) diameter (r = 0.887, p < 
0.001), and LA–supero-inferior direction (SI) diameter (r = 
0.842, p < 0.001) were significantly correlated to LAVI, but 
the degree of correlation was better for LA-ML diameter than 
LA-AP diameter.
Clinical follow-up results
Median duration of follow-up was 22 months. During the fol-
low-up period, 42 cases (26%) underwent composite events. Of 
these 42 cases, 18 patients were admitted due to heart failure 
(5 patients finally died), eight patients due to CVA (one patient 
died), one patient due to acute myocardial infarction (this pa-
tient died), while the death of the remaining 15 patients was 
classified as due to all-cause death. A total of 22 patients (13.5%) 
therefore died. During follow-up period 26 patients underwent 
Table 1. Baseline clinical characteristics
Characteristics Total Significant MVD (n = 113) Non-significant MVD (n = 50) p-value
Age, years 67.5 ± 12.6 65.6 ± 12.8 71.7 ± 11.1 0.004
Female, n (%) 73 (45) 52 (46) 21 (42) 0.634
Body surface area, m2 1.71 ± 0.23 1.70 ± 0.22 1.73 ± 0.26 0.367
Hypertension, n (%) 106 (65) 65 (58) 41 (82) 0.003
Current smoking, n (%) 31 (19) 23 (21) 8 (16) 0.794
Diabetes mellitus, n (%) 39 (24) 25 (22) 14 (28) 0.417
Hypercholesterolemia, n (%) 36 (22) 24 (21) 12 (24) 0.695
Coronary artery disease, n (%) 28 (17) 20 (18) 8 (16) 0.791
Previous stroke or TIA, n (%) 31 (19) 20 (18) 11 (22) 0.519
Anti-platelet agent use, n (%) 57 (35) 33 (29) 24 (48) 0.032
Any anticoagulation use, n (%) 143 (88) 105 (93) 38 (76) 0.004
Statin use, n (%) 32 (20) 21 (19) 11 (22) 0.594
ACEI/ARB use, n (%) 130 (80) 91 (81) 39 (78) 0.711
Beta blocker use, n (%) 59 (36) 32 (28) 27 (54) 0.002
Hemoglobin, g/dL 12.4 ± 2.6 12.5 ± 2.6 12.1 ± 2.7 0.340
eGFR, mL/min/1.73 m2 67.3 ± 21.7 69.3 ± 19.9 62.7 ± 25.0 0.104
BNP, pg/mL (IQR, n = 84) 275.5 (132.5–275.5) 222 (103.0–463.0) 395 (195.0–1081.0) 0.011
CRP, mg/L (IQR, n = 121) 3.4 (1.0–13.2) 3.5 (1.5–17.7) 2.6 (0.8–9.7) 0.141
LVEDD, mm 52.7 ± 8.8 58.7 ± 11.3 58.7 ± 11.3 0.121
LV mass index, g/m2 134.3 ± 43.5 131.1 ± 42.4 141.7 ± 45.6 0.151
LV ejection fraction, % 59.6 ± 12.4 58.7 ± 11.3 61.6 ± 14.6 0.175
LA-AP (IQR), mm 67.0 (66.0–71.0) 68.0 (66.0–73.0) 66.0 (65.0–69.0) 0.004
LA-ML(IQR), mm 67.5 ± 11.8 69.0 (62.0–77.0) 61.0 (56.0–67.0) < 0.001
LA-SI (IQR), mm 86.7 ± 12.0 88.0 (80.0–96.5) 83.0 (76.8–87.3) 0.004
LA volume index (IQR), mL/m2 118.9 (100.2–149.1) 125.2 (103.7–158.2) 106.3 (84.0–128.9) < 0.001
PASP, mm Hg 46.8 ± 16.2 49.5 ± 16.3 40.5 ± 14.1 0.001
MVD: mitral valvular disease, TIA: transient ischemic attack, ACEI: angiotensin converting enzyme inhibitor, ARB: angiotensin receptor blocker, eGFR: esti-
mated glomerular filtration rate, BNP: brain natriuretic peptide, IQR: inter-quartile range, LVEDD: left ventricular end-diastolic dimension, LA: left atrial, 
AP: antero-posterior direction, ML: medio-lateral direction, SI: supero-inferior direction, PASP: pulmonary arterial systolic pressure
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interim MV surgery. Non-MVD patients, mainly those with LV 
systolic and diastolic dysfunction, had a tendency to have more 
composite events than MVD patients, but this difference was 
not statistically significant. The different components of all-
cause death and heart failure readmission did not differ signifi-
cantly between the MVD and non-MVD groups. Previous his-
tory of MV surgery or interim MV surgery was not significantly 
related to composite primary end-points, individually (all p > 
0.05). However, any history of MV surgery, when combined 
both pre-enrollment and interim MV surgery, was related to 
lower incidence of composite primary end-points (hazard ratio 
0.42, 95% CI 0.20–0.85, p = 0.016). In addition, there was no 
significant difference in clinical outcomes between RHD and 
non-RHD groups. In univariate analysis, age, LAVI, eGFR, 
PASP, and Ln CRP was related to composite end-points. In 
multivariate analysis, any history of MV surgery, eGFR, PASP, 
and LAVI were independently related to composite end-points 
(Table 3). LA diameters, however, were not significantly relat-
ed to composite end-points (AP, p = 0.141; ML, p = 0.259; and 
SI, p = 0.142).
Discussion
Main finding of this study is that although rheumatic MVD 
with atrial fibrillation is a major contributor to GLA, other dis-
eases like functional MR and long-standing diastolic dysfunc-
tion combined with atrial fibrillation can result in excessive LA 
enlargement. The event rate during follow-up of 5 years, reached 
26%, which is not negligible percentage regardless of underly-
ing causes. No history of MV surgery, elevated PASP and in-
creased LA volume index are independent predictors of future 
events within this group of patients. Therefore, in patients with 
GLA, accurate measurement of LA volume rather than just di-
ameter is crucial for risk stratification for future events, regard-
less of underlying disease.
Possible mechanisms of excessive LA remodeling
In addition to the classic concept of long-standing pressure or 
volume overload, direct rheumatic involvement14)15) in the left 
atrium would provide a structural substrate for excessive LA 
enlargement, sometimes called LA aneurysm. Previous studies 
showed that pathologic changes of the left atrium differed be-
Table 2. Baseline clinical characteristics according to presence of rheumatic valve disease
Characteristics RHD (n = 72) Non-RHD (n = 91) p-value
Age, years 65.5 ± 11.1 69.1 ± 13.5 0.069
Female, n (%) 37 (53) 36 (39) 0.072
Body surface area, m2 1.67 ± 0.20 1.74 ± 0.24 0.040
Current smoking, n (%) 10 (15) 21 (23) 0.319
Hypertension, n (%) 38 (54) 68 (73) 0.013
Diabetes mellitus, n (%) 18 (26) 21 (23) 0.643
Hypercholesterolemia, n (%) 13 (19) 23 (25) 0.348
Coronary artery disease, n (%) 10 (14) 18 (19) 0.396
Stroke or TIA, n (%) 15 (21) 16 (17) 0.496
Anti-platelet agent use, n (%) 15 (21) 57 (79) 0.001
Any anticoagulation use, n (%) 68 (94) 75 (82) 0.029
Statin use, n (%) 10 (14) 22 (24) 0.136
ACEI/ARB use, n (%) 54 (77) 76 (82) 0.472
Beta blocker use, n (%) 17 (24) 42 (45) 0.006
Hemoglobin, g/dL 12.5 ± 2.4 12.4 ± 2.8 0.801
eGFR, mL/min/1.73 m2 71.7 ± 18.4 63.9 ± 23.5 0.019
CRP, mg/L (IQR; n = 121) 2.8 (1.5–18.6) 3.7 (0.9–12.3) 0.590
BNP, pg/mL (IQR; n = 84) 142 (70.5–264.4) 398.5 (219.5–803.1) < 0.001
LVEDD, mm 50.8 ± 6.4 54.2 ± 10.0 0.008
LV mass index, g/m2 117.9 ± 33.3 147.3 ± 46.3 < 0.001
LV ejection fraction, % 59.8 ± 10.0 59.4 ± 14.2 0.865
LA volume index, mL/m2 127.1 (108.5–167.0) 110.4 (89.8–146.1) 0.002
LA-AP, mm 67.0 (66.0–73.0) 67.0 (66.0–70.0) 0.651
LA-ML, mm 68.5 (62.3–73.8) 64.0 (57.0–72.0) 0.030
LA-SI, mm 89.0 (80.0–99.0) 83.0 (77.0–89.0) 0.003
PASP, mm Hg 46.1 ± 16.2 47.3 ± 16.3 0.660
RHD: rheumatic heart disease, TIA: transient ischemic attack, ACEI: angiotensin converting enzyme inhibitor, ARB: angiotensin receptor blocker, eGFR: es-
timated glomerular filtration rate, CRP: c-reactive protein, IQR: inter-quartile range, BNP: brain natriuretic peptide, LVEDD: left ventricular end-diastolic 
dimension, LA: left atrial, AP: antero-posterior direction, ML: medio-lateral direction, SI: supero-inferior direction, PASP: pulmonary arterial systolic pressure
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tween RHD and non-RHD groups; there was a higher preva-
lence of fibrosis, post-inflammatory changes, Aschoff body, 
and higher expression of inflammatory markers in the RHD 
group than the non-RHD group.2)16) Rheumatic pancarditis 
not only causes MV regurgitation, but also damages the entire 
heart by weakening its tissues.7) A diseased LA wall is there-
fore primed to dilate, especially when significant valve regurgi-
tation co-exists. In our study, patients with underlying RHD 
had a significantly larger left atrium than non-RHD patients, 
which supports role of rheumatic involvement in left atrium 
to make GLA. Another interesting finding in our study is that 
even in the absence of significant MR, GLA developed due to 
advanced diastolic dysfunction such as hypertrophic cardiomy-
opathy and constrictive pericarditis. This observation is con-
trary to classical concepts that rheumatic MVD is a unique de-
terminant of excessive LA remodeling. Moreover, the duration 
of pressure overload to the LA was usually shorter in these dia-
stolic dysfunctional patients than rheumatic MVD patients. 
As a recent study showed, some genetic mutations may be re-
lated to LA size, or some genetic or inherent background could 
predispose to excessive remodeling or aneurysmal change of the 
left atrium.17)
Prognostic importance of LA volume within GLA
GLA can directly compress adjacent bronchopulmonary struc-
tures,18) restrict LV movement,19) result in thrombus formation 
even in patients taking anticoagulation medicines, and/or ele-
vate pulmonary venous pressure as a reflection of long-standing 
LV diastolic dysfunction. The mean 2- or 3-year mortality rate 
was as high as 14%, and the all-event rate was 26%. An inter-
esting finding is that the dogma of “the bigger the worse”5) can 
be applied even at the stage of excessive remodeling or aneurys-
mal changes of the left atrium. Some study results also support 
favorable effects of LA volume reduction procedure for the prog-
nosis.7) Although causality is not certain, history of MV surgery 
was related to better prognosis in our study, it might suggest 
MV surgery improve the prognosis even in the stage of giant 
LA. However, this refers to LA volume rather than directional 
LA dimensions. In our study, LA-AP diameter was modestly 
but significantly correlated with LA volume. This could be 
due to asymmetric expansion during the remodeling process, 
especially greater expansion in the ML direction than the AP 
direction due to limited mediastinal space. Considering this, 
we recommend actual 3D-based measurements in cases with 
excessive LA remodeling.20) LA volume measurements based 
on echo data have some limitations due to assumption by 
methods such as the prolate-ellipsoidal method,11) area-length 
method, and biplane Simpsons’ method9) that the LA is oval-
shaped. We therefore argue that cardiac computed tomography 
or cardiac magnetic resonance imaging would provide more re-
Table 3. Univariate and multivariate analyses for composite end-points
Variables
Univariate analysis Multivariate analysis
HR (95% CI) p-value HR (95% CI) p-value
Age, years 1.036 (1.007–1.065) 0.013 1.012 (0.983–1.042) 0.421
Ln LA volume index, mL/m2 2.558 (1.022–6.404) 0.045 3.589 (1.306–9.910) 0.013
PASP, mm Hg 1.024 (1.006–1.043) 0.010 1.021 (1.003–1.040) 0.025
GFR, mL/min/1.73 m2 0.976 (0.962–0.991) 0.001 0.982 (0.966–1.000) 0.045
Total history of MV surgery 
(pre-enrollment + interim surgery) 
0.415 (0.204–0.847) 0.016 0.419 (0.191–0.917) 0.030
Ln LA-AP, mm 14.60 (0.412–517.7) 0.141
Sex, female 1.178 (0.643–2.158) 0.595
Hypertension 1.052 (0.558–1.980) 0.876
Diabetes mellitus 0.929 (0.444–1.944) 0.874
Pre-enrollment MV surgery 0.439 (0.173–1.119) 0.085
Significant MVD 0.638 (0.339–1.204) 0.165
Rheumatic heart disease 0.695 (0.375–1.290) 0.249
ACEI or ARB use 0.146 (0.356–1.561) 0.436
Beta blocker use 1.023 (0.544–1.923) 0.945
Oral anticoagulation use 0.582 (0.244–1.387) 0.222
Ln BNP, pg/mL (n = 84) 1.412 (0.977–2.043) 0.067
Ln CRP, mg/L (n = 121) 1.231 (1.022–1.482) 0.029
Hemoglobin, g/dL 0.922 (0.828–1.026) 0.138
LV ejection fraction, % 0.986 (0.962–1.009) 0.234
HR: hazard ratio, LA: left atrial, PASP: pulmonary arterial systolic pressure, GFR: glomerular filtration rate, MVD: mitral valvular disease, ACEI: angiotensin 
converting enzyme inhibitor, ARB: angiotensin receptor blocker, Ln: natural logarithm, CRP: C-reactive protein, BNP: brain natriuretic peptide, LV: left ven-
tricular
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liable measurement than echo data in cases with GLA.21) 
Limitations of this study include its retrospective nature, use 
of an echo-database from single tertiary referral hospital, and a 
heterogeneous patient group. Furthermore, it was not possible 
to control for all related prognostic factors.
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